A009290 Stock Overview
Operates as a human healthcare provider in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Kwang Dong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,480.00 |
| 52 Week High | ₩8,500.00 |
| 52 Week Low | ₩5,010.00 |
| Beta | 0.40 |
| 11 Month Change | -7.43% |
| 3 Month Change | -12.04% |
| 1 Year Change | -23.46% |
| 33 Year Change | -22.82% |
| 5 Year Change | -21.26% |
| Change since IPO | 157.29% |
Recent News & Updates
There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding
Aug 06
Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals
Mar 25Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking
Mar 20Recent updates
There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding
Aug 06Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals
Mar 25Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking
Mar 20Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?
Apr 29Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?
Apr 06Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?
Mar 18Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?
Mar 01Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?
Feb 14Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
Feb 01Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly
Jan 19If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late
Jan 06Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend
Dec 24
Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?
Dec 18Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?
Dec 04What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?
Nov 21Shareholder Returns
| A009290 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 6.6% | -3.0% | 2.3% |
| 1Y | -23.5% | 6.3% | -3.8% |
Return vs Industry: A009290 underperformed the KR Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: A009290 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A009290 volatility | |
|---|---|
| A009290 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A009290 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A009290's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 1,050 | Sung-Won Choi | www.ekdp.com |
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti-inflammatory agents, neuropsychiatric solvent, digestive organ agent, antibiotic, and vitamins. The company also offers supplements for low content vitamin, mineral or vital energy substance and quasi drugs.
Kwang Dong Pharmaceutical Co., Ltd. Fundamentals Summary
| A009290 fundamental statistics | |
|---|---|
| Market cap | ₩218.84b |
| Earnings (TTM) | ₩33.89b |
| Revenue (TTM) | ₩1.61t |
6.5x
P/E Ratio0.1x
P/S RatioIs A009290 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A009290 income statement (TTM) | |
|---|---|
| Revenue | ₩1.61t |
| Cost of Revenue | ₩1.30t |
| Gross Profit | ₩302.69b |
| Other Expenses | ₩268.80b |
| Earnings | ₩33.89b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 845.47 |
| Gross Margin | 18.83% |
| Net Profit Margin | 2.11% |
| Debt/Equity Ratio | 44.8% |
How did A009290 perform over the long term?
See historical performance and comparison